Physician profile
Clinton Lauritsen
NPI 1154696326
$188,107.11
in general payments reported to CMS, 2019-2025
16 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $14K · 2021: $8,225 · 2022: $34K · 2023: $50K · 2024: $911 · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $56K · Honoraria: $20K · Food and Beverage: $5,600 · Travel and Lodging: $2,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $55,645.50 |
| Honoraria | $19,695.00 |
| Food and Beverage | $5,599.91 |
| Travel and Lodging | $2,805.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $70,944.06 | 2022-2023 | Trudhesa |
| Amgen INC. | $45,337.19 | 2019-2022 | |
| Allergan, INC. | $23,836.45 | 2019-2020 | |
| Abbvie INC. | $21,870.51 | 2022-2025 | |
| Axsome Therapeutics, INC. | $20,974.75 | 2025 | Symbravo |
| Amneal Pharmaceuticals LLC | $2,625.00 | 2025 | Brekiya |
| Teva Pharmaceuticals USA, INC. | $774.23 | 2019-2025 | Austedo, Ajovy |
| Pfizer INC. | $515.80 | 2023-2025 | |
| Lundbeck LLC | $374.67 | 2019-2023 | Vyepti |
| Supernus Pharmaceuticals, INC. | $363.37 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $179.78 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $145.75 | 2022 | |
| Impel Pharmaceuticals LLC | $87.22 | 2025 | Trudhesa |
| Lilly USA, LLC | $41.24 | 2020-2025 | Emgality |
| Upsher-Smith Laboratories LLC | $20.78 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Lauritsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.